Adlai Nortye Partners with ASK Pharm on Promising Cancer Drug for China Market
Adlai Nortye licenses AN9025, an experimental pan-RAS cancer drug, to ASK Pharm for development in Greater China in a deal worth up to $230 million.
/ 1 item
#ANL↓